Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirfenidone in Dermatomyositis Interstitial Lung Disease
NCT03857854Phase 3Unknown
- Sponsor
- Gyre Pharmaceuticals
- Start
- Jun 2018
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pirfenidone in dermatomyositis-associated interstitial lung disease (DM-ILD) (2 arms), sponsored by Gyre Pharmaceuticals. Primary endpoint: Relative change from baseline of Forced Vital Capacity at 52 Weeks. Status: unknown.
02
Drugs
pirfenidone
03
Conditions
dermatomyositis-associated interstitial lung disease (DM-ILD)
Beyond the preview
Go deeper on NCT03857854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03857854.